Natick, Massachusetts, United StatesFounded 201862+ employeesSION
$292M raisedGrowth· last: series c (Mar 2024)· 2 rounds
Backed by(10 investors)
Enavate Sciences · LeadOrbiMed · Lead+8 more
We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.
